Derazantinib and Atezolizumab in Patients With Urothelial Cancer

NCT04045613 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Derazantinib 300 mg once daily monotherapy
DRUG: Derazantinib 200 mg once daily + atezolizumab 1200 mg
DRUG: Derazantinib 300 mg once daily+ atezolizumab 1200 mg
DRUG: Derazantinib 200 mg twice daily + atezolizumab 1200 mg
DRUG: Derazantinib 300 mg once daily monotherapy (QD)
DRUG: Derazantinib 300 mg once daily + atezolizumab 1200 mg
DRUG: Derazantinib 200 mg twice daily monotherapy

Sponsor

Basilea Pharmaceutica